Sector: healthGLP
Conviction from: Serenity
52-week range: 35.1264.16
Novo Nordisk is a Danish pharmaceutical company specializing in diabetes and obesity care, including insulin and GLP-1 therapies such as Ozempic and Wegovy.
3 tracked filer(s) hold this · 0 opened, 1 added, 2 trimmed in 30-JUN-2026
Aggregate 13FScore 60 — mean of 3 scored holder(s) · buyers (new/add) avg 76. Higher = the smart money in this name has the better track record.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|
| Steve Cohen / Point72 | 76 | Added +104% | 3,635,198 | $174,271,392 | 0.2% |
| Paul Tudor Jones / Tudor | 63 | Trimmed -33% | 1,228,282 | $58,883,839 | 0.1% |
| Ancora | 40 | Trimmed -3% | 3,102 | $148,710 | 0.0% |
Beyond 13F — activists, insiders, politicians & research
4 disclosed trade(s) by 3 filer(s).
Watching · 2 mention(s), 0 personal-position post(s) · first 2025-10-20 · last 2026-01-18
“I'm a bull that's excited about Greenland trade tensions.
US defense like $UAVS and $DPRO are likely to benefit. Same with rare earth/critical materials.
Can't say the same about the pharma bulls in $NVO, European luxury like $LVMH, or possibly big tech.
As you mentioned, I agree it's just noise to the AI trade.” post →
All 2 tweet(s) mentioning this ticker
| Date | Tweet |
|---|
| 2026-01-18 | I'm a bull that's excited about Greenland trade tensions.
US defense like $UAVS and $DPRO are likely to benefit. Same with rare earth/critical materials.
Can't say the same about the pharma bulls in $NVO, European luxury like $LVMH, or possibly big tech.
As you mentioned, I agree it's just … → · 107 likes · 18,623 views |
| 2025-10-20 | @capybara_830 Honestly $NBIS, $WLAC, then splitting $NVO into $TSM + $AMZN calls 6 months out sounds beautiful.
There’s 2x rate cuts and a recent correction going into the best seasonal months. Now’s the best time to go long if any. → · 12 likes · 3,868 views |
| Report | Date | Stance |
|---|
| #104 — State of the Themes: Long GOOGL, Asian Outperformance and the Age of Virality | 2025-08-18 | SHORT |
| #102 — GLP-1s: The Second Serving - Revisiting our GLP-1 Basket | 2025-07-24 | SHORT |
| #92 — Market Memo: Talk to Me, Goose | 2025-04-13 | SHORT |
| #84 — Market Memo: Healthcare's AI-Powered Trump Card | 2025-02-09 | SHORT |